• Login
    View Item 
    •   DSpace Home
    • Stony Brook University
    • Stony Brook Theses & Dissertations [SBU]
    • View Item
    •   DSpace Home
    • Stony Brook University
    • Stony Brook Theses & Dissertations [SBU]
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsDepartmentThis CollectionBy Issue DateAuthorsTitlesSubjectsDepartment

    My Account

    LoginRegister

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Phospho-Sulindac Inhibits Pancreatic Cancer Growth: The Role of NFATc1

    Thumbnail
    View/Open
    Murray_grad.sunysb_0771E_11008.pdf (3.965Mb)
    Date
    1-Aug-12
    Author
    Murray, Onika T.
    Publisher
    The Graduate School, Stony Brook University: Stony Brook, NY.
    Metadata
    Show full item record
    Abstract
    While significant progress has been made in the battle against pancreatic cancer, it ranks 4th in cancer-related deaths in the U.S. Lending to the lethality of the disease is its ability to grow virtually undetected. Once pancreatic cancer is diagnosed, chances are that it has advanced beyond the point of surgical resection, as well as having become quite resistant to chemotherapy. While some chemotherapeutic agents have been able to improve patients' short-term quality of life, the impact on long-term survival has been minimal. The Nuclear Factor of Activated T-cells (NFAT) family is a calcineurin-responsive group of transcription factors initially identified as regulators of T-lymphocyte activation, though they are ubiquitously expressed in cells throughout the body. In particular, NFATc1 has been shown to be overexpressed in pancreatic cancer, thus adding to the aggressive nature of the disease. In preliminary studies with our novel compound, phospho-sulindac (P-S), NFATc1 gene expression and protein levels were elevated in response to treatment. This finding prompted us to study the effects of P-S both in the absence and the abundance of NFATc1. My research focuses specifically on the effects that altered expression of NFATc1 (by genetically and pharmacologically silencing or by overexpressing it) has on pancreatic cancer growth in vitro and in vivo. We found that when the expression of NFATc1 was abrogated either by RNAi or pharmacological inhibition, pancreatic cancer cells were more responsive to treatment with P-S. In the same way, overexpressing the NFATc1 gene made the pancreatic cancer cells less responsive to treatment with P-S. NFATc1 localization is indicative of its activity, with nuclear localization being the active form. Treatment of pancreatic cancer cells with P-S facilitated the cytosolic localization of NFATc1. NFATc1 knock-down and overexpression animal models were generated and the effect of P-S on tumor growth was analyzed. We observed the greatest reduction in tumor growth in our NFATc1 knock-down model. We conclude that P-S is a potentially important agent for the treatment of pancreatic cancer and that NFATc1 localization and activation in response to our compound may play a role in its pharmacological action.
    Description
    141 pg.
    URI
    http://hdl.handle.net/1951/59799
    Collections
    • Stony Brook Theses & Dissertations [SBU] [1955]

    SUNY Digital Repository Support
    DSpace software copyright © 2002-2023  DuraSpace
    Contact Us | Send Feedback
    DSpace Express is a service operated by 
    Atmire NV
     

     


    SUNY Digital Repository Support
    DSpace software copyright © 2002-2023  DuraSpace
    Contact Us | Send Feedback
    DSpace Express is a service operated by 
    Atmire NV